

Declaration

Before discovery of antidepressant activity of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone (Phenotropil) known earlier as nootropic, antidepressant activity of nootropics had been unknown; therefore there were no reasons to assume the antidepressant activity of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone as well. Nootropics are used as a part of a complex therapy for treatment of depression and many other mental disorders only for correction of memory impairment. Before filing the present Application for Invention, during more than 20 years of practical use of nootropics, including usage of substances close in composition to the applied one, in clinical and experimental pharmacology, as well as their scientific study during this period, there was no evidence of existence of nootropics antidepressant activity. There were no cases of cure of depression or even gaining the effect of remission of depressed mood as a result of monotherapy by nootropics in clinical and experimental pharmacology. That is why the antidepressant activity of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone revealed by us was unexpected and the obtained results were remarkable because discovery of the antidepressant effect of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone, especially its effectiveness in treatment depression of different types, stands out among the inventions not only of pyrrolidone derivatives but also of antidepressants of different pharmacological and chemical groups.

Date: May 05, 2009

Signature:



Akhapkina V.I.